Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers
US12209091B2 · kind B2 · utility
1Cited by
0References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 25, 2020 |
| Grant date | Jan 28, 2025 |
| Priority date | — |
| Expiry date | Sep 30, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.